Dr. Ulevitch is a Venture Partner at 5AM Ventures. Previously, he was Professor and Chairman of the Department of Immunology at The Scripps Research Institute, where he is a Professor and Chairman Emeritus. For nearly three decades, Dr. Ulevitch has performed research to understand the role of the immune system in human disease.
He serves as a Scientific Advisor to Aravis Ventures, a European life science venture capital fund and previously served as an advisor to the Lombard Odier Immunology Fund. There he evaluated numerous biotechnology companies over a 15-year span. Dr. Ulevitch serves on the Scientific Advisory Boards of Cleave Biosciences, Igenica Biotherapeutics, Pulmatrix and RuiYi (previously Anaphore). He was formerly a member of the Scientific Advisory Boards at Envoy (acquired by Takeda) and Ikaria.
Dr. Ulevitch received an A.B. from Washington and Jefferson College and a Ph.D. in Biochemistry from the University of Pennsylvania.